Scientific Session
Immunobiology
Petter Brodin, MD, PhD
Karolinska Institut
Stockholm, Sweden
Disclosure(s): Astra Zeneca: Equity interest (Ongoing); Cytodelics AB: Ownership Interest (Ongoing); Johnson & Johnson: Grant/Research Support (Terminated, December 31, 2024); Kancera AB: Employee (Ongoing); Novo Nordisk: Equity interest (Ongoing); Pfizer: Grant/Research Support (Ongoing); Pixelgen Technologies: Advisor or Review Panel Member (Ongoing); Sention Health AB: Ownership Interest (Ongoing); SOBI: Consultant (Terminated, April 3, 2024)